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Pre-hospital plasma transfusion: a valuable
coagulation support or an expensive fluid
therapy?
Christian Fenger-Eriksen1, Dietmar Fries2, Jean-Stephane David3, Pierre Bouzat4, Marcus Daniel Lance5,
Oliver Grottke6, Donat R. Spahn7, Herbert Schoechl8,9 and Marc Maegele10*
Two recent clinical trials with conflicting results have
refuelled the discussion on pre-hospital plasma in trauma.
The multicentre, cluster-randomized PAMPer trial assessed
the efficacy and safety of two units of pre-hospital plasma
versus standard care without plasma in 501 trauma patients
at risk for haemorrhagic shock during air medical transport
to a designated US trauma centre [1]. The mortality at 30
days was lower in the plasma compared to the standard
care group (23% vs 33%; p = 0.03). The randomized,
placebo-controlled COMBAT trial compared the same
plasma volume versus isotonic saline in 144 haemorrhagic
shocked trauma patients within a US ground EMS and a
single US trauma centre but mortality at 28 days did not
differ between trial groups (15% vs 10%; n.s.) [2]. Table 1
summarizes the basic characteristics of both trials. The
results from both trials need to be viewed with caution
against their limitations and may not be translated directly
into routine without addressing a number of critical issues.
A single drop in blood pressure as an inclusion criterion
for both trials is problematic as pre-hospital hypotensive
episodes can have non-bleeding reasons (e.g. anaesthesia,
cardiac, spinal trauma or wrong readings), and, in
PAMPer, half of the patients had received pre-hospital
intubation/mechanical ventilation while for COMBAT no
details were provided. Both trials aimed for patients “at
risk for haemorrhagic shock” or “thought to be due to
acute blood loss” but no signs of bleeding were considered
for inclusion. Notably, 111 patients in PAMPer had
received unspecified pre-treatment prior to inclusion
which may have introduced bias. The time span for in-
clusion expanded over 3 years with trauma care subject to
change over time, e.g. the increasing widespread use of
antifibrinolytic tranexamic acid (TXA). In COMBAT, 10%
of patients had received TXA while its use was not
reported for PAMPer.
There was high mortality difference at 24-h and 28/
30-days within both control arms which had assumingly
received comparable US standard trauma care after
hospital admission (Table 1). With identical entry criteria,
this difference may only be explained by differences in
injury severity, volume status and further pattern and/or
patient care; but no specific details were provided. The
comparison of injury severity between both trials is
difficult due to different scores applied. However, the
mortality in PAMPer was higher than in COMBAT and
that reported elsewhere which limits the external validity
of findings. In the European RETIC trial on early coagula-
tion factor concentrates versus FFP in trauma the 30-day
mortality was only 7.4% despite an ISS of 34 [3]. The
German Trauma Registry (TR-DGU) confirms a mortality
< 10% for an ISS 20–23 [4]. In PAMPer, there was no cli-
nical benefit for plasma on the sequalae of hypovolaemic-
haemorrhagic shock as 32% versus 29% of patients died in
haemorrhagic shock.
The underlying mechanism by which the two units of
pre-hospital plasma may have promoted lower mortality
in PAMPer remains speculative. In both trials, no relevant
improvements in standard/viscoelastic coagulation assays
were reported after pre-hospital plasma. A statistically
relevant but clinically insignificant shorter prothrombin
ratio was reported for the plasma group (1.2 vs 1.3) but
cannot account for the observed difference in mortality.
In COMBAT, more patients in the plasma group had an
INR > 1.3. The INR quantifies only pro-coagulants and
does not mirror concentrations of inhibitors. In trauma,
INR can be prolonged despite upregulated thrombin
generation potential [5]. Moreover, the INR of FFP is 1.3
[6]. Any beneficial effect of plasma to correct slightly
elevated INR is futile and plasma has primarily an effect
on coagulation parameters with extended volumes and
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performs best in patients bleeding and coagulopathic. The
negative effects of plasma need to be considered [7]; in
COMBAT a trend towards higher MOF was observed in
the plasma group (6% vs 2%).
A large proportion of patients did not receive massive
transfusion and most arrived at the hospital with the
absence of clinical/laboratory signs of relevant coagulo-
pathy. Furthermore, the number of pRBCs transfused in
both trials was low and without any statistical difference.
Notably, half of the PAMPer patients had received pre-
hospital pRBCs. Moreover, no difference in mortality in
massively transfused patients independent of pre-hospital
plasma administration was reported. Accordingly, only
patients with less severe injury would have benefited from
pre-hospital plasma. In PAMPer, 42% of the standard care
patients had received pre-hospital pRBCs (26% in the FFP
group) and almost twice as much crystalloids prior to hos-
pital admission. Both measures could have contributed to
the higher mortality in the standard care group in PAMPer.
The transfusion trigger, however, remains unknown. For
COMBAT, the authors admitted that median fibrinogen
levels and other coagulation factors on hospital arrival were
within reference ranges; and slightly higher in the standard
of care non-FFP group.
As demonstrated, the pre-hospital administration of
plasma to trauma patients is technically/logistically feasible
both in air and ground EMS. However, the different conclu-
sions of the trials leave the question unsolved to whether
pre-hospital plasma may be of any clinical benefit for the
target population. As PAMPer patients had received pre-
hospital pRBCs and more intravenous fluids a simple
“volume” effect cannot be excluded. Risk-benefits need to
be balanced against other challenges, e.g. infrastructure,
logistics and costs, and an early goal-directed approach
using coagulation factor concentrates (e.g. fibrinogen,
which is critically depleted first during bleeding [8]), TXA,
and permissive hypotension along with surgical bleeding
control to limit further blood loss and stabilize coagulation
function pre-hospital may be an alternative as outlined in
the updated European trauma guideline [9]. Protective ef-
fects to the glycocalyx and endothelial barrier integrity have
been linked to the fibrinogen component rather than to
plasma per se [10]. A median 3.8 g fibrinogen concentrate
can increase clot stability by 5.2mm at 5 min of viscoelastic
test initiation while TXA can decrease lysis by 5.4% [11].
From a European perspective, the blind pre-hospital
administration of plasma to potentially non-coagulopathic
patients with short transportation times cannot be
justified. More clearly defined studies are necessary to
justify logistics and costs associated with pre-hospital
blood product transfusion.
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